StockPriceToday
Applovin Corp (APP)
About Applovin Corp
AppLovin Corporation provides software solutions and services that help mobile app developers market their applications, monetize their content, and grow their user bases worldwide. The company's focus on mobile app ecosystem support has made APP stock price sensitive to mobile gaming trends and digital advertising spending patterns.
AppLovin's platform enables app developers to acquire users through targeted advertising while providing tools to monetize their apps through in-app advertising and purchases. The company's machine learning algorithms optimize ad performance and user engagement across its network.
The company's own mobile games portfolio generates revenue while providing data insights that improve its advertising platform effectiveness. AppLovin's expansion into connected TV advertising and e-commerce demonstrates its strategy for growth beyond mobile gaming, influencing APP stock price movements.
AppLovin's technology capabilities and data analytics provide competitive advantages while its comprehensive platform approach serves diverse developer needs. The company's ability to innovate and adapt to changing mobile app monetization requirements remains important for its continued growth and market positioning.
APP Stock 12 Month Chart
Latest News for APP
The stock has been cut in half this year.
AppLovin stock plunged 20% on a Q2 revenue miss, but Q3 guidance stays strong. Click here to read more about APP.
AppLovin’s stock was one of the S&P 500’s biggest decliners on Thursday, as investors reacted not just to underwhelming earnings but also to new information suggesting that the company’s ...
Other Popular Stocks
QuidelOrtho Corporation (QDEL) is a leading provider of diagnostic testing solutions, offering rapid point-of-care tests, molecular diagnostics, and immunoassays serving healthcare providers globally.
Sportradar Group AG (SRAD) is a leading global sports technology company providing data, content, and technology solutions to sports leagues, betting operators, media companies,...
Contineum Therapeutics Inc. (CTNM) is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases and related disorders.